Tamculosin for urinary retention in hip fracture patients
- Conditions
- Health Condition 1: M00-M99- Diseases of the musculoskeletal system and connective tissueHealth Condition 2: M968- Other intraoperative and postprocedural complications and disorders of musculoskeletal system, not elsewhere classified
- Registration Number
- CTRI/2022/05/042897
- Lead Sponsor
- AIIMS Bhubaneswar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.All patients undergoing hip fracture surgery (ORIF or arthroplasty)
2.>=18 years of age.
3.Patients willing to participate
1.History of neurogenic bladder or urological problems requiring routine intermittent catheterization
2.Patients unable to take an oral medication
3.Patient who would require an indwelling catheter for other reasons, or patients who needed catheterisation during admission to the emergency for voiding difficulty
4.Patients with systolic blood pressure <100 mmhg or orthostatic hypotension
5.Pregnant women
6.Associate trauma of spine or pelvis
7.Patients taking medications for lower urinary tract symptoms or who had previously undergone prostatectomy
8.Patients with severe liver or kidney disease
9.Patients taking strong inhibitors of CYP3A4 (ketoconazole, itraconazole, clarithromycin, ritonavir/ritonavir, lopinavir/ritonavir, or conivaptan), use of a 5-alpha reductase inhibitor medication, the use of sildenafil, tadalafil, or vardenafil, history of an allergy or sensitivity to tamsulosin or other alpha-blockers (alfuzosin, doxazosin, prazosin,
Terazosin, or phenoxybenzamine),
10.Uncontrolled concomitant illness including, but not limited to, ongoing or active infection
11.Congestive heart failure, unstable angina pectoris, cardiac arrhythmia,
12.Psychiatric illness
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method